The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Chemotherapy in hormone-refractory prostate cancer: Docetaxel with and without VT122.
Gouri Shankar Bhattacharyya
No relevant relationships to disclose
Newell Bascomb
No relevant relationships to disclose
Hemant Malhotra
No relevant relationships to disclose
Ghanashyam Biswas
No relevant relationships to disclose
Shailesh Arjun Bondarde
No relevant relationships to disclose